β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

ABSTRACT:

Background and objectives

There is a paucity of data available to describe drug dialyzability. Of the available information, most was obtained before implementation of modern hemodialysis membranes. Our study characterized dialyzability of the most commonly prescribed β-blockers in patients undergoing high-flux hemodialysis.

Design, setting, participants, & measurements

Patients on hemodialysis (n=8) were recruited to an open label, pharmacokinetic, four-way crossover trial. Single doses of atenolol, metoprolol, bisoprolol, and carvedilol were administered on separate days in random order to each patient. Plasma and dialysate drug concentrations were measured, and dialyzability was determined by the recovery clearance and arterial venous difference methods.

SUBMITTER: Tieu A 

PROVIDER: S-EPMC5969458 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature